We look back to look forward and predict whether three of 2025's biggest disappointments can turn it around in 2026.
SELLAS Life Sciences Group recently reported that its Phase 3 REGAL trial of galinpepimut‑S (GPS) in Acute Myeloid Leukemia had reached 72 of the 80 overall-survival events required for final analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback